MixNMatch COVID Booster Study - A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA Vaccines (NIH / DMID)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Sars-cov-2 Infection.
    Infectious Diseases
  • Age: Between 18 - 55 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. You completed your original COVID-19 vaccine at least 12 weeks ago
    2. You are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures
    3. You are determined to be in good health by medical history, targeted physician examination and clinical judgement of the investigator
    4. Female participants of childbearing potential may be enrolled in the study, if all of the following apply:
      • You practiced adequate contraception for 28 days prior to the first dose of vaccine (Day 1)
      • You agree to continue adequate contraception through 3 months following the booster dose
      • You have a negative pregnancy test at screening and on the day of the first vaccine dose (Day 1)
      • You are not currently breastfeeding

You may not be eligible for this study if the following are true:

    1. You previously had a COVID-19 infection
    2. You previously received any research coronavirus vaccines (SARS-CoV, MERS-CoV) or any COVID-19 monoclonal antibodies in the last 90 days or are currently taking part in or plan to take part in another research study
    3. You have a history of anaphylaxis, hives, or other serious allergic reactions that required medical attention after receiving a vaccine or any nanolipid particles
    4. You received any research study product 28 days before study enrollment
    5. You received or plan to receive any other non-study vaccine 28 days before or after any dose of the study vaccine
    6. You have any bleeding conditions diagnosed by a doctor or experience any significant bruising or bleeding with intramuscular injections or blood draws
    7. You have an immunocompromised or immunosuppressive condition or any immune-mediated disease
    8. In the last 6 months, you received any systematic immunosuppressants or medications that affect your immune system for more than 14 days before your screening visit
    9. You received any immunoglobulin or blood-derived products within 90 days before the first study vaccine
    10. You are acutely ill or have a fever 72 hours before or at the time of the study vaccine dosing visit



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.